Title: Regents’ Professor of Physics
Employer: Emeritus, Arizona State University, Tempe AZ
When and why did you become a SITC member?
I've been a member for 2
years as a prostate cancer advocate. There are no known cures for metastatic
prostate cancer and immunotherapy has the potential for a cure.
Can you briefly explain the work you are doing in the field?
I’m very much involved in the prostate cancer support/advocacy
community which includes organizing seminars/conferences, leading an Us TOO
prostate cancer support/education group, and giving talks on immunotherapy at
such places as the Mayo Hospital in PHX.
Who or what inspired you to choose this specific career path?
What are some of the biggest challenges you are facing in the field?
If you’ve seen one case of prostate cancer, you’ve seen one case of
prostate cancer. Each one is unique. Being a solid tumor cancer that is
generally not highly mutated, immunotherapy has not had much of an impact
(yet!) on treatment of prostate cancer.
What topic(s) do you plan to write about for The Sentinel, SITC’s new blog?
Immunotherapy and its application to metastatic prostate
cancer.
What do you hope readers will gain from this new blog?
PCa
is the most diagnosed cancer in men. 1 in 6 are diagnosed, and of those
diagnosed, 1 in 6 die from it. Research activity is far lacking compared to
breast cancer. I wish to promote awareness to the problem of prostate cancer.
No comments:
Post a Comment